ELEV

Elevation Oncology, Inc. (ELEV) | Rumor.io

Elevation Oncology

ELEV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ELEV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Jun 9

Elevation Oncology, Inc. ($ELEV) has entered into a definitive merger agreement with Concentra Biosciences, whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share plus a non-tradeable contingent value right.
The contingent value right represents the right to receive 100% of the closing net cash in excess of $26.4 million and 80% of any net proceeds received within five years from the disposition of EO-1022.
The merger agreement has been announced, with the acquisition expected to close at $0.36 per share, and the company's stock has been halted for the first time.

Generated by AI

Sentiment

Of the messages about ELEV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +16.96
Bearish	—	—	—	0% -16.96

Bullish· Mar 20

Elevation Oncology, Inc. has $93 million in cash and $1.60 per share in cash, with several upcoming catalysts that could lead to a 200% increase in value.
The company's HER3 program has the potential to be a game-changer, and a buyout or partnership could happen if the program is successful.
Elevation Oncology, Inc. has a strong cash position, with only $31 million in debt, making it an attractive target for acquisition or partnership.

Bearish· Mar 20

Elevation Oncology, Inc. (ELEV) has a significant cash burn rate, which may not be sustainable, given its preclinical asset pipeline.
The company has made major restructuring moves, including discontinuing its lead program, slashing jobs, and reducing its workforce by 70%, indicating potential issues with its product development.
ELEV's institutional holding has dropped to 67%, and some investors are questioning the company's direction, citing concerns about its cash reserves, product pipeline, and management team.

Generated by AI

Topics

Of the messages about ELEV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	0%	0%
Macro	—	0%	0%	0%
Earnings	—	0%	0%	0%
Controversies	—	0%	0%	0%
Announcements	—	100%	100%	100%
Analysts	—	0%	0%	0%

Analysts· Jul 20

Elevation Oncology (ELEV) has been initiated with an "outperform" rating by multiple analysts, including Wedbush, Cowen, and SVB Leerink, with price targets ranging from $20 to $27.
Analysts from various firms, such as Wedbush, Cowen, and SVB Leerink, have initiated coverage on ELEV with "outperform" ratings, indicating a positive outlook on the company's prospects.
The price targets for ELEV have been set at $20 by SVB Leerink, $24 by JPMorgan Chase, and $27 by Wedbush, reflecting varying levels of optimism among the analysts.

Announcements· Jun 9

Elevation Oncology (ELEV) has entered into a definitive merger agreement with Concentra Biosciences, whereby Concentra will acquire ELEV for $0.36 in cash per share plus a contingent value right.
The contingent value right represents the right to receive 100% of the closing net cash in excess of $26.4 million and 80% of any net proceeds received within five years following closing from any disposition of EO-1022.
The transaction is expected to close in July 2025, subject to customary conditions, including the availability of at least $26.4 million of cash.

Technical Analysis· Jan 9

$ELEV has shown a similar move to early 2023, with a recent example of a buy-program seen in $CCCC.
The setup and pattern for $ELEV are present, with a potential re-test of $2.
$ELEV has a 1H rising channel with a falling wedge, with upside targets including $2.00, $2.10, and $2.40-$2.50+.

Generated by AI

Community

Of the messages about ELEV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	21.86%
Newcomers	0%	0%	0%	78.14%

Regulars· Jan 8

The stock has seen significant gains, with some participants making 200-300% profits, and others considering selling for a profit.
The current 4H setup suggests potential for a move back up to $1.30-1.50, with a focus on holding dips to $1.00 for entry opportunities.
The stock's low float and high short percentage have created a "perfect storm" for a potential move, with some participants warning of a possible "downright silly" day for shorts.

Newcomers· Jan 13

New investors are expressing satisfaction with their average investment in Elevation Oncology, Inc. (ELEV).
Some newcomers are showing interest in ELEV as a potential long-term investment, despite considering it a "random Penny stock gamble".
ELEV is being discussed as a promising investment opportunity by some newcomers.

Generated by AI

Also Discussed

Investors talking about ELEV also mention

#	Name	Attention
1	LVTX - LAVA Therapeutics N.V.	——
2	Sera Prognostics, Inc. Class A Common StockSERA	0%0
3	TScan Therapeutics, Inc.TCRX	0%0
4	C4 Therapeutics IncCCCC	0%-0.01
5	Shattuck Labs, Inc.STTK	0%+0
6	Pyxis Oncology, Inc. Common StockPYXS	0%new
7	Prelude Therapeutics IncorporatedPRLD	0%0
8	GRCL - Gracell Biotechnologies Inc.	——
9	Viatris Inc.VTRS	0%0
10	FIAC - Focus Impact Acquisition Corp.	——